ANZ Faces Legal Battle as Former CEO Shayne Elliott Sues Over A$13.5 Million Bonus Dispute 
Apple App Store Injunction Largely Upheld as Appeals Court Rules on Epic Games Case 
SoftBank Eyes Switch Inc as It Pushes Deeper Into AI Data Center Expansion 
Nvidia Develops New Location-Verification Technology for AI Chips 
Microsoft Unveils Massive Global AI Investments, Prioritizing India’s Rapidly Growing Digital Market 
Westpac Director Peter Nash Avoids Major Investor Backlash Amid ASX Scrutiny 
United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff 
EU Court Cuts Intel Antitrust Fine to €237 Million Amid Long-Running AMD Dispute 
SoftBank Shares Slide as Oracle’s AI Spending Plans Fuel Market Jitters 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
Evercore Reaffirms Alphabet’s Search Dominance as AI Competition Intensifies 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
Rio Tinto Signs Interim Agreement With Yinhawangka Aboriginal Group Over Pilbara Mining Operations 
Air Transat Reaches Tentative Agreement With Pilots, Avoids Strike and Restores Normal Operations 
Samsung SDI Secures Major LFP Battery Supply Deal in the U.S. 
GameStop Misses Q3 Revenue Estimates as Digital Shift Pressures Growth 
JD.com Pledges 22 Billion Yuan Housing Support for Couriers as China’s Instant Retail Competition Heats Up 
Boryung Pharmaceutical has added Eli Lily's Gemzar among the anti-cancer drugs that it has rights to distribute in South Korea.
Boryung also has distribution rights to such anti-cancer drugs as Oxalitin (oxaliplatin) and Genexol (paclitaxel).
Boryung CEO Ahn Jae-hyun promised to continue growing its anti-cancer portfolio as the company's focal point.
Gemzar (gemcitabine), a nucleoside metabolic inhibitor, is mainly a pancreatic cancer treatment drug.
Combined with other drugs, Gemzar is used for the treatment of metastatic breast cancer, advanced ovarian cancer, and non-small cell lung cancer.
Gemzar posted 14.2 billion won in revenue in South Korea last year.
